Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial

BACKGROUND: EXamining everolimus In a Study of Tuberous sclerosis 3 (EXIST-3) demonstrated significantly reduced seizure frequency (SF) with everolimus vs placebo. In this study, we evaluate the long-term efficacy and safety of everolimus for tuberous sclerosis complex (TSC)-associated treatment-ref...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Clin Pract
Autors principals: Franz, David N., Lawson, John A., Yapici, Zuhal, Ikeda, Hiroko, Polster, Tilman, Nabbout, Rima, Curatolo, Paolo, de Vries, Petrus J., Dlugos, Dennis J., Voi, Maurizio, Fan, Jenna, Vaury, Alexandra, Pelov, Diana, French, Jacqueline A.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6276348/
https://ncbi.nlm.nih.gov/pubmed/30564495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000514
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars